Clinical trials: WHO Grade 3 Glioma
5-aminolevulinic Acid, Fluorescence-guided Resection
5-Aminolevulinic Acid for Photodynamic Diagnosis of Malignant Glioma
This phase III, multicenter, open-label, single-arm study will evaluate the ability of 5-aminolevulinic acid hydrochloride (5-ALA HCl) powder for oral solution to visualize malignant tissue during surgery, and its safety, in…
- Conditions
- 5-aminolevulinic Acid, Fluorescence-guided Resection, High-Grade Glioma (WHO III-IV)
- Trial name
- NCT06160492
- Testing
- 5-Aminolevulinic Acid Hydrochloride Powder for Oral Solution
- Where
- 2 sites in China
- Volunteers
- 79 people
- Sponsor
- Lee's Pharmaceutical Limited
WHO Grade II Glioma
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
- Trial name
- NCT04458272
- Testing
- DS-1001b
- Where
- 11 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
High Grade Glioma, Astrocytoma
Study of Olutasidenib and Temozolomide in HGG
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
- Conditions
- High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
- Trial name
- NCT06161974
- Testing
- Olutasidenib + TMZ
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- Rigel Pharmaceuticals
High-Grade Glioma (WHO III-IV)
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
This clinical trial aims to determine if FG001 can assist surgeons in identifying the difference between tumor and healthy tissue during surgery in participants with newly diagnosed high-grade glioma.
- Trial name
- NCT07609472
- Testing
- FG001
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- FluoGuide A/S
Recurrent Glioblastoma, High-Grade Glioma (WHO III-IV)
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
This is an open label, single arm, prospective, and pilot study. Eligible patients will be enrolled after acquiring the signed informed consent and then will receive the treatment of re-RT combined with FUS (FUS + re-RT) on an…
- Conditions
- Recurrent Glioblastoma, High-Grade Glioma (WHO III-IV), Brain Tumor Recurrent, Brain Tumor Adult
- Trial name
- NCT04988750
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 7 people
- Sponsor
- NaviFUS Corporation
High-grade Glioma, WHO Grade Ⅳ Glioma
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4…
- Trial name
- NCT06482905
- Testing
- Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
- Where
- 4 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Tcelltech Inc.
High-Grade Glioma (WHO III-IV), Cerebral Vascular Conditions Requiring Surgical Intervention
Evaluation of Image Quality and Safety of the MyVeo Surgical Visualization Headset During Standard Neurosurgical and Reconstructive Procedures Using Compatible Microscopes.
This study looks at how well the MyVeo surgical visualization headset works during routine surgeries. MyVeo is a wearable device that helps surgeons see the surgical area in high detail, including blood flow and tissue…
- Conditions
- High-Grade Glioma (WHO III-IV), Cerebral Vascular Conditions Requiring Surgical Intervention, Conditions Requiring Plastic and Reconstructive Surgery
- Trial name
- IMED-MYVEO (NCT07164053)
- Testing
- MyVeo is an all-in-one surgical visualization headset used with compatible surgical microscopes and other medical imaging systems in the area of neurosurgery, ENT, spine, plastic and reconstructive su
- Where
- 2 sites in Spain, Switzerland
- Volunteers
- 32 people
- Sponsor
- Leica Microsystems (Schweiz) AG
Glioma, Glioma Tumor Recurrence
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
The purpose of this Phase I clinical study is to evaluate the safety, preliminary efficacy and pharmacokinetic characteristics of BC008-1A injection in subjects with recurrent CNS WHO grade 4 glioma.
- Conditions
- Glioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM)
- Trial name
- NCT06773481
- Testing
- BC008-1A
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Advanced Solid Tumor, CNS Tumor
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
The phase 1b study is aimed at determining the pediatric recommended phase 2 dose (RP2D) of Infigratinib. The phase 2 study will evaluate efficacy and safety of infigratinib.
- Conditions
- Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
- Trial name
- NEWEL (NCT05222165)
- Testing
- Infigratinib
- Where
- 10 sites in United States, Canada and 1 more
- Sponsor
- Helsinn Healthcare SA